Georgia McGrath

Introduction Polycystic Ovarian Syndrome (PCOS) affects 1 in 8 women, making it one of the most common hormonal conditions. Despite this, many people experience years of symptoms before receiving a diagnosis, leading to frustration, uncertainty and delayed treatment. Following a 14 year international collaboration between researchers, clinicians, charities and those living with the condition, a major change was announced in May 2026. The name PCOS will be replaced with PMOS (Polyendocrine...

Introduction Alzheimer’s disease (AD), along with other forms of dementia, is currently the leading cause of death in the UK. It causes profound, progressive decline in cognitive, physical and emotional health. Its effects are felt not only by the individual, but by their friends and family too. Although current medications given under the NHS can help improve symptoms, these cannot prevent disease progression. However, recent advances in pharmacological therapies could provide hope for those...

Introduction Glucagon-like peptide 1 (GLP-1) agonists have transformed obesity treatment in recent years. Medications such as semaglutide have become widely used therapies, enabling weight loss that was previously only possible with invasive surgery. Their use continues to grow, with around 1 in 8 US adults reportedly prescribed these in 2025. While efficacious, a significant proportion of weight lost during GLP-1 agonist therapy is attributable to reductions in lean muscle mass. This can be...